About HKTDC | Media Room | Contact HKTDC | Wish List Wish List () | My HKTDC |
Save As PDF Print this page

Import Controls Adopted on Substance Used in Epilepsy Drugs

The Drug Enforcement Administration has adopted as final without change a May 2016 interim final rule placing brivaracetam, including its salts, into schedule V of the Controlled Substances Act. As a result, this substance will continue to be subject to the regulatory controls and administrative, civil and criminal sanctions applicable to the importation, exportation, manufacture, distribution, reverse distribution, dispensation, research, and conduct of instructional activities and chemical analysis of schedule V substances. These include the following.

  • all importation and exportation of this substance must be in compliance with 21 USC 952, 953, 957 and 958 and in accordance with 21 CFR part 1312
  • any activity involving this substance that is not authorised by, or is in violation of, the Controlled Substances Act or its implementing regulations is unlawful and may subject the person to administrative, civil or criminal sanctions
  • any person who handles or desires to handle this substance must be registered with the DEA to conduct such activities
  • all labels, labelling and packaging for commercial containers of this substance must comply with 21 USC 825 and 958(e) and be in accordance with 21 CFR part 1302
  • every DEA registrant who possesses any quantity of this substance must take an initial inventory and update it every two years
Content provided by Picture: HKTDC Research
Comments (0)
Shows local time in Hong Kong (GMT+8 hours)

HKTDC welcomes your views. Please stay on topic and be respectful of other readers.
Review our Comment Policy

*Add a comment (up to 5,000 characters)